Highlighting the implications and innovations of clinical trial research to advance evidence-based medicine and public health.
Joined March 2026
- Tweets59
- Following1
- Followers209
- Likes0
What statement in our JAMA+ Trials poll best reflects your opinion on extension studies?
📊 Cast your vote on 1 of our 5 options in the latest JAMA+ Trials Poll and share your perspective.
🔗 Vote now: ja.ma/4yIkWiu
What’s your take on extension studies to clinical trials?
Do they provide longer-term insights, increase participants’ motivation to enroll in the original trial, or something else?
📊 Cast your vote in the latest JAMA+ Trials Poll.
🔗 Vote now: ja.ma/4yIkWiu
Presented at #ESMO26 from @JAMA_current:
In low erythroblastic oncogene B 2 (ERBB2) advanced #BreastCancer, trastuzumab rezetecan showed benefit in hormone receptor–positive and hormone receptor-negative disease.
ja.ma/3W4qiH5
Presented at #ESMO26 from @JAMA_current: For low erythroblastic oncogene B 2 (ERBB2) advanced #BreastCancer, trastuzumab rezetecan improved progression-free survival vs chemotherapy in both chemotherapy-naive patients and the overall population.
ja.ma/4ievcIS
Finding relevant clinical trial evidence can be time-consuming.
JAMA+ Trials brings together nearly 3,000 curated trial reports published across the JAMA Network, making it easier to search, browse, and discover clinical trial research in one place.
ja.ma/4iacmCL
JAMA+ Trials brings together research, commentary, and educational content designed to help readers interpret and communicate trial evidence.
🔗 Explore the latest research and educational resources: ja.ma/3U6SU1V
Looking for trial evidence across specialties?
@JAMAplusTrials offers a searchable collection of recent trial reports published across the JAMA Network.
📚 Discover research, commentary, and educational content: ja.ma/4iyXeAf
🧵 How useful are "pragmatic" clinical trials for informing real-world decision-making?
In the latest @JAMAplusTrials poll, only 10.9% of respondents believed that nearly all trials labeled as "pragmatic" successfully provide useful evidence for real-world decisions.
🔖 This October's Trial Theme of the Month focuses on extension studies in #ClinicalTrials, where long-term findings depend on how comparison groups are defined and how attrition and selection bias are handled.
🔗 Read the latest editorial: ja.ma/4zqdoBD
🔖 JAMA+ Trials is a new platform that highlights the implications and innovations of #ClinicalTrial research from across the JAMA Network to advance evidence-based #medicine and public #health.
📬 Learn more and subscribe to the email newsletter: ja.ma/3VsMSsO
💭 In your opinion, how many clinical trials that claim to be "pragmatic" are successful in providing useful evidence for real-world decision-making?
JAMA+ Trials wants to hear from you.
🔗 Share your perspective: ja.ma/4iMBSQB
📢 JAMA+ Trials wants to hear from you.
Share your perspective in our latest poll and help spark discussion around the future of clinical trial research.
📊 Vote now: ja.ma/3TniYWb
📢 Share your opinion: How many clinical trials that claim to be "pragmatic" actually provide useful evidence for real-world decision-making?
📊 Vote now and join the discussion: ja.ma/4h5U1rm
#ClinicalTrials #Research #Evidence
How many clinical trials that claim to be "pragmatic" are successful in providing useful evidence for real-world decision-making?
💭 Cast your vote in the latest JAMA+ Trials Poll and share your perspective.
📊 Take the poll: ja.ma/4yMrE7l
💭 In your opinion, how many clinical trials that claim to be "pragmatic" are successful in providing useful evidence for real-world decision-making?
@JAMAplusTrials wants to hear from you.
🔗 Vote now: ja.ma/4hhDAHf
Among infants with neonatal opioid withdrawal syndrome cared for with the #EatSleepConsole approach, symptom-based opioid dosing was associated with a shorter time to medical readiness for discharge than a scheduled opioid taper.
🔗 ja.ma/3V5d8sV
ALT JAMA study: Symptom-based opioid dosing decreases time to medical readiness for infants with neonatal opioid withdrawal syndrome (NOWS). Population: 185 males, 198 females. Findings: symptom-based dosing 9.18 days vs. scheduled opioid taper 11.61 days.
📣 This JAMA+ Trials Theme of the Month examines how #pragmatic clinical trials are intended to generate evidence for real-world clinical decisions without sacrificing research rigor.
📬 Learn more about this trial and subscribe to the newsletter: ja.ma/3V60NES
💭 In your opinion, how many clinical trials that claim to be "pragmatic" are successful in providing useful evidence for real-world decision-making?
JAMA+ Trials wants to hear from you.
🔗 Share your perspective: ja.ma/4rlS2T0
Among older surgical patients with #frailty, assignment to home-based prehabilitation before elective noncardiac surgery did not improve 30-day disability scores or reduce postoperative complications vs usual care.
🔗 ja.ma/4ya0Jmj
📣 This JAMA+ Trials Theme of the Month examines how #pragmatic clinical trials are intended to generate evidence for real-world clinical decisions without sacrificing research rigor.
📬 Learn more about this trial and subscribe to the newsletter: ja.ma/4yOqd8s